Showing results (131-140 of 175) with videos related to
Sort By:
Pageof 18
Cancer Medicine|March 21, 2022
A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancerBenjamin Solomon, Ana Callejo, Jair Bar, et al.The Oncologist|April 17, 2026
Characterization and Clinical Management of Adverse Events Following Treatment with Repotrectinib: A TRIDENT-1 AnalysisAlexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.The Oncologist|May 8, 2026
Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysisAlexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.Journal of the National Cancer Institute|June 7, 2007
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional studyFumiko Taguchi, Benjamin Solomon, Vanesa Gregorc, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2009
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALKAlice T Shaw, Beow Y Yeap, Mari Mino-Kenudson, et al.Targeted Oncology|October 24, 2023
A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaAlbiruni R Abdul Razak, Hung-Ming Wang, Jang-Yang Chang, et al.Clinical and Translational Radiation Oncology|March 11, 2026
Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapyAndrea R Filippi, Jair Bar, Daniel C Christoph, et al.Nature Reviews. Clinical Oncology|March 16, 2021
COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trialsAakash Desai, Justin F Gainor, Aparna Hegde, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2020
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid TumorsJayesh Desai, Hui Gan, Catherine Barrow, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2022
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R StudyNicolas Girard, Jair Bar, Pilar Garrido, et al.Pageof 18